https://scholars.lib.ntu.edu.tw/handle/123456789/535885
標題: | IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients | 作者: | Chuang J.Y. Yang S.S. Lu Y.T. Hsieh Y.Y. Chen C.Y. SHAN-CHWEN CHANG Chang C.S. Yeh H.Z. JIA-HORNG KAO |
公開日期: | 2009 | 卷: | 41 | 期: | 6 | 起(迄)頁: | 424-430 | 來源出版物: | Digestive and Liver Disease | 摘要: | Background and aims: Host genetic factors may affect clinical outcomes of hepatitis C virus (HCV) infection; however, the possible mechanisms remain largely unknown. The role of immunopathogenesis in chronic hepatitis C leads to extensive exploration of host immunity including inflammatory cytokines. Methods: We examined interleukin 10 (IL-10) promoter gene polymorphisms at positions -1082, -819, and -592 relative to transcription start site and studied their association with response to 24 weeks of pegylated interferon plus ribavirin treatment in 143 chronic hepatitis C patients, of whom 97 (67.8%) achieved a sustained virologic response (SVR). In addition, 134 healthy adults were used as controls. Results: Of chronic hepatitis C patients, 111 (77.6%) were genotype 1 infection, 32 (22.4%) were genotype 2 infection. Patients with sustained virologic response were younger and had higher pretreatment ALT levels than those without. No statistical difference was found between chronic hepatitis C patients who achieved SVR or not in terms of gender, HCV genotype, pretreatment HCV RNA levels, and severity of liver disease. The serum IL-10 levels were comparable between healthy controls and chronic hepatitis C patients as well as between HCV patients with and without SVR. The distribution of IL-10 promoter gene polymorphisms at positions -1082, -819, and -592 relative to transcription start site was comparable between HCV patients and healthy controls as well as HCV patients with and without SVR. A high frequency of ATA haplotype of common IL-10 promoter gene SNPs was found in both chronic hepatitis C patients (70.3%) and healthy controls (69.8%). However, ATA haplotype was not associated with SVR in chronic hepatitis C patients. Conclusions: Our data fail to demonstrate the influence of IL-10 promoter gene polymorphisms on the response to combination therapy in Taiwanese chronic hepatitis C patients. The impact of genetic variations in IL-10 haplotype on the response to anti-HCV treatment among different ethnic populations deserves further examination. ? 2008 Editrice Gastroenterologica Italiana S.r.l. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-67349099867&doi=10.1016%2fj.dld.2008.09.017&partnerID=40&md5=85d98caa8dc0299eedc797b76160e557 https://scholars.lib.ntu.edu.tw/handle/123456789/535885 |
ISSN: | 1590-8658 | DOI: | 10.1016/j.dld.2008.09.017 | SDG/關鍵字: | interleukin 10; peginterferon alpha2a; peginterferon alpha2b; ribavirin; virus RNA; adult; age distribution; article; controlled study; disease severity; DNA polymorphism; drug response; female; gene frequency; genetic association; genetic variability; genotype; haplotype; hepatitis C; Hepatitis C virus; human; major clinical study; male; priority journal; sex difference; single nucleotide polymorphism; Taiwan; transcription initiation site; treatment duration; Adult; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon Alfa-2a; Interferon Alfa-2b; Interleukin-10; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Ribavirin; Taiwan; Treatment Outcome; Young Adult |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。